Mutations in the glucokinase (GCK) gene result in maturity-onset diabetes of the young (MODY). Pharmacotherapy is not effective in GCK MODY. Thus, nutritional intervention seems to be the only therapeutic option. This study evaluated the effect of the quantity of dietary carbohydrate on glucose levels in 10 GCK mutation carriers: seven with MODY and three with prediabetes. All patients were exposed to high-carbohydrate diets for 2 days and then switched to lowcarbohydrate diets (60% versus 25% of the daily calorie intake) for another 2 days, after a 1-day washout. Glucose levels were assessed by continuous blood glucose monitoring. In patients with GCK MODY on high-carbohydrate diets, glucose levels were significantly higher, and more hyperglycaemic episodes occurred, compared with patients on lowcarbohydrate diets. This short-term observational study suggested that diets with a modestly limited carbohydrate content may improve glycaemic control in patients with GCK MODY.
Introduction
Maturity-onset diabetes of the young (MODY) describes a heterogeneous group of autosomal-dominant forms of diabetes, characterized by pancreatic β-cell dysfunction and an early age of onset. 1 Heterozygous inactivating mutations in the glucokinase (GCK) gene cause one of the most frequent forms of MODY. 2 -4 GCK MODY has a population prevalence in the order of 0.04 -0.1%, 2,4 -6 which corresponds to as many as several hundred thousand subjects on the European continent. The reported proportion of GCK mutations among MODY families varies between 10% and 80%; the differences can probably be attributed to variable identification procedures, with some paediatric centres recruiting more GCK MODY families than other institutes. 3, 5, 6 T Klupa, I Solecka, N Nowak et al.
Dietary carbohydrate and glycaemia in glucokinase MODY
Glucokinase is a key regulatory enzyme of the pancreatic β-cells that is crucial for energy production and insulin secretion. 7 -9 Mutations in the GCK gene increase the threshold for glucose-stimulated insulin secretion. 3,5,6,9 -11 Abnormalities in glucose metabolism in patients with GCK MODY are characterized by modestly elevated fasting blood glucose levels and small postchallenge incremental rises in blood glucose. 1, 2, 5, 12 These abnormalities are already present in early childhood; however, due to the absence of clinical symptoms, they are often not detected until later in life. 3, 5, 6, 12 Unfortunately, there are few therapeutic options for this frequent form of monogenic diabetes. Unlike in MODY caused by mutations in the hepatocyte nuclear factor 1-α (HNF1A) gene, pharmacotherapy with oral hypoglycaemic agents or insulin is not effective in patients with GCK MODY. 13, 14 A discontinuation of pharmacotherapy does not result in a deterioration in their metabolic control. 14, 15 Thus, nutritional intervention seems to be the only therapeutic option that can be considered in GCK MODY. The most effective type of diet in controlling glycaemia in this diabetes subtype remains to be established.
Carbohydrates are the most potent dietary factors that influence postprandial glucose levels and there is a consensus that all patients with diabetes should avoid high glycaemic index carbohydrates. 16 There are different opinions on the proportion of carbohydrate that should make up the diet, and the recommended average daily requirement ranges between 45% and 60% of daily calorie intake. 17 The evidence for these recommendations is weak, and has been labelled 'C' grade. 16 Furthermore, there are no specific guidelines on the best dietary approach to take in forms of monogenic diabetes, such as MODY.
This short-term, observational study evaluated whether a modest limitation of dietary carbohydrate might improve glycaemic control in patients with GCK MODY.
Patients and methods

STUDY POPULATION
Consecutive patients > 18 years of age, with mutations of the GCK gene, were recruited from the Department of Metabolic Diseases, Jagiellonian University Medical College (Krakow, Poland) between January 2008 and July 2010. All patients were carriers of GCK gene mutations that have been previously shown to cause GCK MODY or prediabetes (the latter defined as either impaired fasting glucose, impaired glucose tolerance, or both). 5 These mutations segregated with glucose abnormalities (diabetes or prediabetes) in the families of the study participants. Diagnoses of GCK MODY and prediabetes were established according to current World Health Organization criteria. 18 The study protocol and informed consent procedures were approved by the Ethical Committee of Jagiellonian University. Each participant provided written informed consent.
STUDY DESIGN AND DIETARY INTERVENTIONS
As all diabetes-related pharmacotherapy was discontinued soon after the results of genetic testing were available, patients were treated with diet recommended for ≥ 6 months 16, 17 before undergoing the continuous glucose monitoring system (CGMS) examinations, described below. Then, GCK mutation carriers with either diabetes or prediabetes were exposed to diets rich in carbohydrate (where carbohydrates comprised 60% of the daily calorie intake) for 2 days. After a 1-day washout period, patients were switched to low-carbohydrate The prestudy carbohydrate intake was determined by a dietitian using a local framework food questionnaire, filled out by the patient before study entry, and an interview with the patient. Questions asked by the dietitian covered the portion sizes of 64 food items and a series of adjustment questions. Each patient's ability to evaluate the calorie content of food was checked by means of the food questionnaire.
Patients were instructed to avoid high glycaemic index foods. To facilitate compliance, the proportion of calories derived from fat and protein was not imposed and depended on the patient's preferences. Patients were asked to provide detailed records concerning the composition of their meals during the study.
CONTINUOUS BLOOD GLUCOSE MONITORING
Blood glucose levels were evaluated using a CGMS (MiniMed System Gold CGMS; Medtronic, Northridge, CA, USA) according to the manufacturer's instructions. The CGMS record was performed throughout the study (i.e. the 2 days on the highcarbohydrate diet, the 1 day of washout and the 2 days on the low-carbohydrate diet); the system could provide data for a single reading period of ≤ 6 days. Mean blood glucose levels and the percentage of time spent above the target postprandial blood glucose level (i.e. 7.8 mmol/l) were recorded at each time point. During the period of CGMS recording, patients were instructed to avoid physical exercise beyond their regular daily activities.
STATISTICAL ANALYSES
Statistical analyses were performed with SAS statistical software, version 9.2 (SAS Institute Inc., Cary, NC, USA). Differences in the mean blood glucose level and in the percentage of time spent above the target postprandial blood glucose level between the high-and low-carbohydrate study periods were compared using the Wilcoxon's signed-rank test. A value of P < 0.05 was considered to be statistically significant.
Results
The study population consisted of 10 GCK mutation carriers: seven patients with GCK MODY and three patients with prediabetes. The mean prestudy carbohydrate intake, based on the food questionnaire, was 40% of the daily calorie intake (range 35 -55%). On average, patients consumed an equal percentage of calories from fat and protein (approximately 20% of the daily calorie intake for both fat and protein) when on the high-carbohydrate diet and slightly more fat calories (approximately 40% of the daily calorie intake) when on the low-carbohydrate diet. The characteristics of the study participants are shown in Table 1 .
In all seven patients with GCK MODY who had GCK diabetes, mean blood glucose levels were higher during exposure to the highcarbohydrate diet (7.91 mmol/l; 95% confidence interval [CI] 7.37, 8.45 mmol/l) than while on the low-carbohydrate diet (7.15 mmol/l; 95% CI 6.68, 7.64 mmol/l); a difference of 0.76 mmol/l (95% CI 0.51, 1.00) was observed (P = 0.02).
The mean time-periods spent above the target postprandial blood glucose level were 37.6% (95% CI 27.0%, 48.1%) and 25.9% (95% CI 14.7%, 37.0%) in patients on the high-and low-carbohydrate diets, respectively (P = 0.02); improvements in the postprandial blood glucose level were observed in all seven patients with GCK MODY while on the low-carbohydrate diet.
Five of the seven patients with GCK MODY The carbohydrate content of the diet had no significant impact on blood glucose levels in the three patients with prediabetes who were carriers of GCK mutations. Regardless of diet, in these patients the majority of blood glucose measurements were within the target level and the mean glucose levels were within the range of 6.2 -6.5 mmol/l.
Discussion
This short-term, observational study showed that dietary intervention with a moderate reduction of the carbohydrate content may lower mean blood glucose levels and improve other glycaemic parameters in patients with GCK MODY. In contrast, the low-carbohydrate diet had no effect in the GCK mutation carriers with prediabetes, who did not meet the formal criteria for a diagnosis of diabetes. Two clinical trials evaluating the effects of low-carbohydrate diets in patients with type 2 diabetes consistently showed improvements in glycaemic control. 19, 20 The present study is the first to address this issue in monogenic diabetes; its findings suggest that a diet with a reduced carbohydrate content could be considered in an individual with diabetes due to a GCK mutation who did not reach treatment goals, especially with respect to postprandial hyperglycaemia. This may be important, because effective pharmacotherapy is lacking for the treatment of this subtype of diabetes.
While these results may have a potential impact on clinical practice, one should interpret them with caution: the long-term impact of a diet with a reduced carbohydrate 10, 21 In addition, no systematic research on cardiovascular events has been performed in patients with GCK mutations. Thus, the role of relatively mild hyperglycaemia in the development of macrovascular complications among GCK MODY patients has yet to be established.
One of the limitations of the present study was the lack of patient randomization. In addition, the wash-out period was restricted, due to the limited lifespan of the CGMS sensor, which could only provide a single reading period of ≤ 6 days. Another limitation of the study was the small sample size. It should be noted, however, that as GCK MODY is a relatively rare disease and, as patients are often not willing to accept limitations superimposed by the study design (e.g. diet or limited physical activity), it is often difficult to recruit large numbers of participants to such studies.
In summary, the present study suggests that a diet with a modestly limited carbohydrate intake may improve glycaemic control in patients with GCK MODY. Further randomized controlled studies, in larger populations of patients, are required to clarify the results of the present study.
